CXCL8 and chronic myelogenous leukemia, BCR-ABL1 positive: CXCL8 protein expression was enhanced by BCR-ABL expression and was inhibited by TKIs such as dasatinib and nilotinib, implicating CXCL8 as a useful marker for the monitoring of CML inhibitor efficacy [95].